ArticleEuropean journal of nuclear medicine and molecular imaging2008
Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence.
Article in European journal of nuclear medicine and molecular imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Differentiating radiation necrosis from tumor recurrence: a systematic review and diagnostic meta-analysis comparing imaging modalities.Journal of neuro-oncology · 2023Pooled it
- Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review.Radiation oncology (London, England) · 2019Pooled it
- A meta-analysis on the diagnostic performance of (18)F-FDG and (11)C-methionine PET for differentiating brain tumors.AJNR. American journal of neuroradiology · 2014Pooled it
- Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis.AJNR. American journal of neuroradiology · 2013Pooled it
- Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?Journal of neuro-oncology · 2013Pooled it
- Review
- Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.Frontiers in immunology · 2021Review
- Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.AJNR. American journal of neuroradiology · 2020Review
- Complications of Radiotherapy and Radiosurgery in the Brain and Spine.Neurographics (2011) · 2018Article
- Imaging in neuro-oncology.Therapeutic advances in neurological disorders · 2018Review
- Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics-Relevance to Glioma.Frontiers in neurology · 2018Review
- The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas.Journal of Korean Neurosurgical Society · 2017Article
- ¹⁸F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility.European journal of nuclear medicine and molecular imaging · 2015Article
- How treatment monitoring is influencing treatment decisions in glioblastomas.Current treatment options in neurology · 2015Article
- Pathophysiology, diagnosis, and treatment of radiation necrosis in the brain.Neurologia medico-chirurgica · 2015Review
- Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Frontiers in neurology · 2015Review
- Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.Neurosurgical review · 2014Review
- Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.Neurologia medico-chirurgica · 2014Article
- Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.Neuro-oncology · 2013Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeReliable differential diagnosis between tumour recurrence and treatment-induced lesions is required to take advantage of new therapeutic approaches to recurrent gliomas. Structural imaging methods offer a high sensitivity but a low specificity, which might be improved by neurofunctional imaging. This study aimed to test the hypothesis that incorporation of 18-fluoro-deoxy-glucose positron emission tomography (FDG-PET) increases the accuracy of this differential diagnosis obtained with 201Tl chloride-single-photon emission computed tomography (201Tl-SPECT). MATERIALS AND
methodsSeventy-six patients (mean age 47.72 +/- 16.19 years) under suspicion of glioma recurrence, 42% with low-grade and 58% with high-grade lesions, were studied by (201)Tl-SPECT and FDG-PET, reporting results under blinded conditions using visual analysis. Tumour was confirmed by histological confirmation (23 patients) or clinical and structural neuroimaging follow-up (mean of 2.6 years).
resultsThis population had a high disease prevalence (72%). Globally, highest sensitivity was obtained using 201Tl-SPECT assessed with MRI (96%) and highest specificity using FDG-PET + MRI (95%). FDG-PET appeared slightly better for confirming tumour recurrence, whereas 201Tl-SPECT was superior for ruling out possible recurrence (disease present in 38% of FDG-PET negative explorations). In the high-grade subgroup, there were no false-positive examinations (specificity: 100%), but sensitivity differed among techniques (201Tl-SPECT : 94%; 201Tl-SPECT + MRI: 97%; FDG-PET + MRI: 83%). In the low-grade subgroup, 201Tl-SPECT + MRI showed highest sensitivity (95%) and lowest posttest negative probability (9%); FDG-PET + MRI offered highest specificity (92%) with a posttest negative probability of 35%.
conclusionsFDG-PET does not clearly improve the diagnostic accuracy of (201)Tl-SPECT, which appears to be a more appropriate examination for the diagnosis of possible brain tumour recurrence, especially for ruling it out.
Indexed as
Identifiers
18172642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.